Aktienanalyse zu Phio Pharmaceuticals Corp (PHIO)PHIOPhio Pharmaceuticals Corp

Phio Pharmaceuticals Corp. is a clinical-stage biotechnology company. The Company's INTASYL self-delivering RNAi technology platform is designed to make immune cells more effective in killing tumor cells. It is developing therapeutics that are designed to leverage INTASYL to target specific proteins that reduce the body's ability to fight cancer, without the need for specialized formulations or drug delivery systems. The Company's pipeline is focused on the treatment of cutaneous Squamous Cell Carcinoma (cSCC) and melanoma. Its product pipeline includes PH-762 and PH-894. PH-762 is an INTASYL compound designed to reduce the expression of cell death protein 1 (PD-1). PD-1 is a protein that inhibits T cells’ ability to kill cancer cells and is a clinically validated target in immunotherapy. PH-894 is an INTASYL compound that is designed to silence BRD4, a protein that controls gene expression in both T cells and tumor cells, thereby affecting the immune system as well as the tumor. It operates in the Healthcare sector (PHARMACEUTICAL PREPARATIONS industry).

Phio Pharmaceuticals is not a good buy right now due to its current price of $0.80, a very low RSI of 28.193 indicating oversold conditions, and a significant 1-year change of -48.39%. The company continues to report substantial losses, with net income losses reaching -$4,003,000 in Q1 2026, which raises concerns about its financial health and sustainability.